{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+for+warfarin", "query": { "intervention": "Placebo for warfarin" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 12, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+for+warfarin&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-20T18:01:15.509Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00580216", "title": "Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atrial Fibrillation" ], "interventions": [ { "name": "Idrabiotaparinux sodium", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" }, { "name": "Placebo (for idrabiotaparinux)", "type": "DRUG" }, { "name": "Placebo (for warfarin)", "type": "DRUG" }, { "name": "Avidin", "type": "DRUG" }, { "name": "Placebo (for avidin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3773, "start_date": "2007-12", "completion_date": "2010-10", "has_results": false, "last_update_posted_date": "2016-03-21", "last_synced_at": "2026-09-20T18:01:15.509Z", "location_count": 162, "location_summary": "Mobile, Alabama • Tucson, Arizona • Little Rock, Arkansas + 134 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Mountain Home", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00580216" }, { "nct_id": "NCT00345618", "title": "Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Embolism", "Thrombosis" ], "interventions": [ { "name": "Idrabiotaparinux sodium", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" }, { "name": "Placebo (for idrabiotaparinux sodium)", "type": "DRUG" }, { "name": "Avidin", "type": "DRUG" }, { "name": "Placebo (for warfarin)", "type": "DRUG" }, { "name": "Enoxaparin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3202, "start_date": "2006-06", "completion_date": "2010-10", "has_results": false, "last_update_posted_date": "2016-03-21", "last_synced_at": "2026-09-20T18:01:15.509Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00345618" }, { "nct_id": "NCT06615596", "title": "Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Atrial Fibrillation (AF)" ], "interventions": [ { "name": "discontinue anticoagulation therapy", "type": "BEHAVIORAL" }, { "name": "Anticoagulant drugs", "type": "DRUG" }, { "name": "Catheter Ablation", "type": "PROCEDURE" } ], "intervention_types": [ "BEHAVIORAL", "DRUG", "PROCEDURE" ], "sponsor": "China National Center for Cardiovascular Diseases", "sponsor_class": "OTHER_GOV", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3160, "start_date": "2025-08-05", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-09-20T18:01:15.509Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06615596" }, { "nct_id": "NCT00781391", "title": "Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stroke", "Atrial Fibrillation", "Embolism" ], "interventions": [ { "name": "warfarin tablets", "type": "DRUG" }, { "name": "Edoxaban tablets (high dose regimen-60mg)", "type": "DRUG" }, { "name": "Edoxaban tablets (low dose regimen-30mg)", "type": "DRUG" }, { "name": "placebo warfarin", "type": "DRUG" }, { "name": "placebo edoxaban", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 21105, "start_date": "2008-11", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2019-03-05", "last_synced_at": "2026-09-20T18:01:15.509Z", "location_count": 316, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 308 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Lake Havasu City", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00781391" }, { "nct_id": "NCT00027066", "title": "Warfarin Versus Aspirin Recurrent Stroke Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stroke" ], "interventions": [ { "name": "Active Aspirin", "type": "DRUG" }, { "name": "Active Warfarin", "type": "DRUG" }, { "name": "Aspirin placebo", "type": "DRUG" }, { "name": "Warfarin placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "30 Years to 85 Years" }, "enrollment_count": 2206, "start_date": "1993-06", "completion_date": "2001-11", "has_results": false, "last_update_posted_date": "2011-06-17", "last_synced_at": "2026-09-20T18:01:15.509Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00027066" }, { "nct_id": "NCT00643201", "title": "Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Venous Thrombosis" ], "interventions": [ { "name": "Enoxaparin", "type": "DRUG" }, { "name": "warfarin", "type": "DRUG" }, { "name": "Placebo for apixaban", "type": "DRUG" }, { "name": "Placebo for enoxaparin", "type": "DRUG" }, { "name": "Placebo for warfarin", "type": "DRUG" }, { "name": "apixaban", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5614, "start_date": "2008-07", "completion_date": "2013-03", "has_results": true, "last_update_posted_date": "2014-04-21", "last_synced_at": "2026-09-20T18:01:15.509Z", "location_count": 73, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 68 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Banning", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00643201" }, { "nct_id": "NCT00403767", "title": "An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atrial Fibrillation", "Stroke", "Embolism" ], "interventions": [ { "name": "Rivaroxaban", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" }, { "name": "Matching placebo for Rivaroxaban arm (Warfarin placebo)", "type": "DRUG" }, { "name": "Matching placebo for Warfarin arm (Rivaroxaban placebo)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14269, "start_date": "2006-12", "completion_date": "2010-09", "has_results": true, "last_update_posted_date": "2014-04-29", "last_synced_at": "2026-09-20T18:01:15.509Z", "location_count": 295, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 292 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Geneva", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Pell City", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00403767" }, { "nct_id": "NCT00786474", "title": "Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arterial Thromboembolic Events", "Atrial Fibrillation" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Dalteparin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1884, "start_date": "2009-07", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2016-03-07", "last_synced_at": "2026-09-20T18:01:15.509Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00786474" }, { "nct_id": "NCT01036802", "title": "Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Hypertension" ], "interventions": [ { "name": "Warfarin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "16 Years to 65 Years" }, "enrollment_count": 3, "start_date": "2009-12", "completion_date": "2012-09", "has_results": true, "last_update_posted_date": "2016-05-09", "last_synced_at": "2026-09-20T18:01:15.509Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01036802" }, { "nct_id": "NCT00329238", "title": "Secondary Prevention of Venous Thrombo Embolism (VTE).", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Thromboembolism" ], "interventions": [ { "name": "Dabigatran", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2867, "start_date": "2006-05", "completion_date": null, "has_results": true, "last_update_posted_date": "2014-05-19", "last_synced_at": "2026-09-20T18:01:15.509Z", "location_count": 18, "location_summary": "Mobile, Alabama • Hartford, Connecticut • Clearwater, Florida + 15 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Decatur", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00329238" } ] }